The government has launched a roadmap to grow India's bioeconomy to $691 billion by 2035, aiming to create 30 million jobs. The plan proposes six national bio-missions and a new ₹50,000-crore growth fund to support startup innovation and commercial-scale production.
The government has unveiled a comprehensive strategy to establish India as a global leader in the biotechnology sector. According to the NITI Aayog roadmap, the nation’s bioeconomy is projected to reach a valuation of $691 billion by 2035, up from an estimated $195.3 billion in 2025. This transition is expected to contribute significantly to the country's GDP and generate over 30 million jobs in high-skill areas.
Scaling the Biotech Ecosystem
To achieve this growth, the strategy focuses on transitioning biotechnology from laboratory research to large-scale commercial production. A centerpiece of the policy is the proposal for a ₹50,000-crore BioEconomy Growth Fund, which would provide capital to startups and firms between 2026 and 2035. This funding is designed to address the common challenge of scaling up operations, often known as the 'valley of death' for research-heavy startups, where innovative products struggle to reach the market due to lack of commercial funding.
National Bio-Missions and Regulatory Framework
The roadmap introduces six National Bio-Missions targeting specific high-growth areas, including synthetic biology, climate-resilient agriculture, and next-generation biopharmaceuticals. These missions aim to streamline regulatory approvals and strengthen intellectual property protections, which are essential for attracting private sector investment. The government also intends to support this transition with incentives modeled after existing manufacturing programs, focusing on biomanufacturing and the integration of artificial intelligence in biotechnology research.
Growth Context and Investor Considerations
India's bioeconomy has demonstrated rapid expansion, reportedly growing 16-fold since 2014. For investors, this sector shift highlights an increased emphasis on companies involved in R&D, specialized laboratory equipment, contract research organizations, and biotechnology firms. While the long-term potential is significant, the actual impact on listed companies will depend on how effectively the proposed growth fund and regulatory reforms are executed. The success of this vision is also tied to the development of specialized talent, with new engineering biology courses being introduced to build the necessary workforce.
Investors should monitor the specific guidelines of the proposed BioEconomy Growth Fund and the actual rollout of the national missions. Progress in infrastructure development and the ease of navigating the updated regulatory environment will be critical indicators of whether the projected growth targets can be met.